Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.
Journal: Nature communications
Published: November 05, 2024
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 22, 2015
Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Journal: Journal of clinical pharmacology
Published: May 07, 2015
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 03, 2014
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 03, 2014
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Journal: The Lancet. Oncology
Published: December 03, 2014
Showing 1-7 of 7
Last Updated: 09/26/2026